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Irene Zwarts  
General Introduction 
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Metabolic imbalance caused by our modern lifestyle 
Changes in our lifestyle have resulted in a worldwide increase in the prevalence of 
chronic metabolic diseases such as type 2 diabetes mellitus (T2DM), non-alcoholic fatty 
liver disease (NAFLD), cardiovascular disease (CVD) and certain types of cancer. These 
obesity-related lifestyle diseases are currently the largest health threat in our society 
and are mainly caused by excessive energy intake and a sedentary lifestyle. Fructose 
may be an important contributor to this pandemic as its consumption in the past 50 
years has dramatically increased to more than 10% of our daily calorie intake, mainly 
due to the use of inexpensive corn-based sweeteners such as high-fructose corn syrup 
(HFCS) that was introduced in the early 1970’s[1,2]. Studies aimed to elucidate the 
mechanisms that contribute to the worldwide increase in metabolic health problems 
have traditionally focused on the development of insulin resistance in metabolically 
active organs such as adipose, muscle and liver. Only recently, however, the importance 
of the gut as an endocrine organ with a major role in whole body energy homeostasis 
has been underscored.  
 
Nutrient digestion and absorption in the gut 
The primary role of the gastrointestinal tract is to ensure nutrient absorption which 
in most cases entails digestion of dietary components before they can be transported 
into enterocytes (Table 1). Active transport over the plasma membrane takes place via 
membrane transporters at the cost of energy in the form of ATP. Alternatively, passive 
transport is mediated by facilitative transporters, channels and, in case of small 
hydrophobic molecules, direct diffusion. Dietary carbohydrates, fats and proteins are 
macronutrients that provide the building blocks for cellular structures as well as energy 
after being absorbed by the small intestine. Simple sugars are readily transported into 
and through enterocytes and, therefore, cause an acute raise in blood glucose levels. In 
contrast, complex carbohydrates, like starch, consist of long chains of glucose molecules 
and first need to be digested before they can be absorbed. This results in a more gradual 
release of glucose molecules into the bloodstream and more stable plasma glucose 
levels. Complex carbohydrates are hydrolyzed into smaller polysaccharides by a-amylase 
in the oral cavity and the proximal part of the small intestine. Polysaccharides and 
disaccharides are further digested in the small intestine by enzymes in the brush border 
membrane (BBM) of enterocytes, like sucrase-isomaltase (SI), maltase-glucoamylase 
(MGAM) and lactase-phlorizin hydrolase (LPH)[3]. The resulting monosaccharides can 
subsequently be transported into enterocytes by various membrane transporters. 
Glucose molecules are absorbed from the intestinal lumen by the high affinity sodium-
dependent glucose cotransporter 1 (SGLT1) and, with a lower affinity, by the facilitative 
glucose transporter 2 (GLUT2, SLC2A1). Transport of glucose from the enterocyte into 
the bloodstream is primarily mediated by GLUT2, as it localizes both to the apical and 
basolateral membrane[4].  
 
Dietary proteins, composed of chains of amino acids, are digested in the stomach 
into polypeptides by the enzyme pepsin. Large polypeptides enter the duodenum where 
they are further digested by the pancreatic enzymes trypsin and carboxypeptidase and 
by brush border enzymes. Di- and tripeptides are taken up in the proximal part of the 
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small intestine by hydrogen-peptide transporter (PepT1), a process that is dependent on 
a pH-gradient which is maintained by transepithelial sodium/hydrogen exchange[5–7]. 
Free amino acids are absorbed into enterocytes via various sodium-dependent (proton-
coupled transporter PAT1) and sodium-independent transporters[8]. Amino acids can be 
transported over the baso-lateral membrane via the portal vein into the systemic 
circulation and subsequently to all tissues. Within cells, amino acids can be used as 
building blocks to synthesize needed proteins. 
 
Dietary fats are predominantly ingested in the form of triglycerides (TGs). Since fat is 
highly hydrophobic it forms lipid droplets, which are emulsified and, upon lipolysis, 
solubilized in the intestinal lumen by bile. Pancreatic lipase in turn can break the TGs 
down into monoacylglycerol and free fatty acids (FAs) that can diffuse through the cell 
membrane into enterocytes[9]. Within the enterocytes, absorbed FAs and 
monoacylglycerols are reassembled into triglycerides and as such transported towards 
peripheral tissues via lipoproteins called chylomicrons (reviewed in[10]).  
 
Lastly, undigestible food components will reach the colon and are either digested by 
gut bacteria or excreted. Resistant starch for example is digested by gut microflora 
which produce short chain fatty acids (SCFAs). SCFA can be absorbed by the host and 
have beneficial effects on human metabolism[11].  
 
 
Table 1 Key hormones, secretory stimuli, and physiological processes occurring along 
the gut axis[12]. The details are based on mouse data. 5-HT, serotonin; CCK, 
cholecystokinin; EECs, enteroendocrine cells; GIP, glucose-dependent insulinotropic 
polypeptide; GLP-1 and GLP-2, glucagon-like peptides 1 and 2; Insl5, insulin-like peptide 





The role of the gut in whole-body metabolism 
The contribution of the gastrointestinal tract to energy homeostasis has long been 
considered to be limited to the digestion and absorption of nutrients. Nowadays, 
however, it is generally accepted that the intestine is not only involved in nutrient 
absorption, but is also a metabolically active organ with endocrine functions governing 
systemic metabolism[13]. The major contribution of the gastrointestinal tract in the 
regulation of systemic energy homeostasis became apparent when gastrointestinal 
(bariatric) surgery was shown to be a very effective treatment for obese patients 
suffering from T2DM[14,15]. Although the mechanisms underlying the success of 
bariatric surgery are still being investigated, it is clear that the beneficial effects are not 
simply due to decreased food intake or reduced intestinal absorption of nutrients. 
Hypertension and blood glucose levels for example already improve after bariatric 
surgery before the weight loss occurs, indicating that bariatric surgery is beneficial for 
metabolic outcomes independent of weight loss[16]. 
 
The gut controls energy balance via various mechanisms but the intestine by itself 
also directly impacts total energy expenditure, due to its large size and high turnover 
rate of epithelial cells of 3-5 days. In addition, it has been shown that the intestine is an 
insulin-sensitive organ and during intestinal insulin resistance, which can develop 
independently of systemic insulin resistance, the intestine increases lipogenesis and 
lipoprotein synthesis resulting in dyslipidemia in obese patients[17,18].  
 
Nutrient sensing in the gut is essential to regulate energy homeostasis and can be 
mediated via at least three different mechanisms. 1) Nutrient status can be 
communicated by the gut-brain axis via the vagus nerve to match food intake to energy 
demands; 2) The secretion of gut hormones, which regulate energy homeostasis by 
acting as satiety and hunger signals that control food intake and are needed to 
effectively regulate catabolic and anabolic reactions in other organs; 3) The gut 
microbiota can significantly affect the inflammatory and metabolic status of the host. 
These three nutrient sensing mechanisms are explained in more detail below. 
 
Gut-brain axis 
The systemic regulation of energy homeostasis is governed by the hypothalamus, an 
area within the central nervous system (CNS) that regulates feeding behavior[19]. The 
brain receives information about the energy status from peripheral organs via the vagus 
nerve and via signaling molecules like gut hormones and leptin, an adipose tissue 
derived satiety molecule[20,21]. This information from the periphery is used to match 
feeding behavior to energy demand.  
 
The nervous interaction between the gut and brain is mainly taken care of by the 
enteric nervous system (ENS), a large network of neurons and glial cells in the gut which 
plays a key role in the regulation of energy homeostasis[12]. This so-called “second 
brain” consist of approximately 70% vagal afferent nerves that send information from 
gut hormones and gastric mechanoreceptors to the CNS. Interestingly, it has been 
shown that both caloric restriction and a high-fat diet (HFD) disturb the gut-brain axis in 
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mice. Indeed, in both situations, the effects of satiety signal peptides on the vagal 
afferent nerves of the ENS are blunted, while the ghrelin signaling is enhanced, 
ultimately promoting obesity[22,23]. 
 
Gut hormones 
The gut produces many peptides that regulate satiety, including cholecystokinin 
(CCK), peptide YY (PYY), oxyntomodulin (OXM), glucose-dependent insulinotropic 
peptide (GIP), glucagon-like peptide 1 (GLP-1) and the appetite stimulant ghrelin. 
Incretins are gut hormones which are secreted upon food intake and have insulinotropic 
properties. The main incretins are GIP and GLP-1 which promote insulin secretion in 
response to glucose. Since GIP loses its insulinotropic effect during insulin resistance, 
most research focuses on GLP-1[24]. GLP-1 improves beta-cell function through 
enhanced sensitivity to glucose, higher beta-cell survival and increased proinsulin gene 
and protein expression, ultimately resulting in enhanced glycemic control[25–27]. Since 
GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) upon secretion, DPP-4 
inhibitors as well as GLP-1 receptor agonists have been studied as drug candidates to 
treat obesity and T2DM. Several GLP-1 based drugs have reached the clinic and they 
promote glycemic control without causing hypoglycemic side effects in T2DM 
patients[28]. The effect on weight control, however, differs between specific GLP-1 
receptor agonists and DPP-4 inhibitors, where several GLP-1 based treatments result in 
weight loss while others are weight-neutral[29]. 
 
Surprisingly, it has recently been shown that Metformin, the most commonly 
prescribed drug for T2DM, maintains its glucose-lowering property if it can selectively 
and exclusively exert its effects via the gut. The improved glycemic control after 
intestinal Metformin treatment was ascribed to changes in the gut microbiome, 
increased GLP-1 levels and influencing the gut-brain axis[30,31]. Before this discovery, 
the beneficial actions of Metformin were primarily attributed to the liver where it causes 
a reduction in hepatic glucose production. Low doses of Metformin, however, improve 
glycemic control due to its effects in the gut[32]. These findings potentially can help to 
avoid adverse effects that are associated with higher doses of Metformin treatment.  
 
Microbiota  
Gut bacteria influence energy homeostasis mainly via retrieving energy from 
otherwise indigestible nutrients, producing SCFAs, causing low-grade systemic 
inflammation and regulating bile acid homeostasis[33–35]. Importantly, the gut 
microbiota composition is crucial for the metabolic outcome since substrate cross-
feeding between bacterial stains determine the fermentation end-products. The gut 
microbiota composition is unique for each individual and can be modulated by the diet, 
especially by the presence of indigestible dietary components. In addition, dietary 
prebiotics, (indigestible dietary fibers) and probiotics (live bacteria) are used to influence 
the intestinal microbiota composition in order to reach an improved metabolic 
status[36]. 
SCFAs are volatile fatty acids, produced by microbiota. The total SCFA pool and the 
relative contribution of a specific SCFA is determined by diet and gut microbiota 
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composition (reviewed in[37]). The three most studied SCFAs, butyrate, propionate and 
acetate, are suggested to promote metabolic health. Interestingly, supplementation of 
any of these SCFAs has beneficial effects on obesity and insulin resistance in mice fed a 
HFD, although the extent of these effects differ between the specific SCFAs[38]. The 
mechanisms to explain these effects on metabolism are plural, including, the reduction 
of food intake, the stimulation of gut hormones and the downregulation of PPARg 
signaling in adipose tissue[38,39].  
 
Gut microbiota derived lipopolysaccharide (LPS) causes a pro-inflammatory status 
that is associated with metabolic perturbations such as leptin resistance and inadequate 
satiety signal transmission through the vagus nerve[23,40,41]. Interestingly, an altered 
gut microbiota was found after bariatric surgery and this was associated with reduced 
levels of low-grade systemic inflammation, explaining at least in part the metabolic 
beneficial effects independently of weight loss[42,43]. 
 
Nutrient sensors in the gut 
Several nutrient sensing mechanisms are present in the intestinal tract to match food 
intake with energy homeostasis. Here, we review the most important intestinal nutrient 
sensors that are activated by dietary cues and that govern whole-body metabolism. The 
superfamily of G-protein coupled receptors (GPCRs) are membrane bound receptors 
that are activated by nutrients and other cues present in the intestinal lumen. In 
addition, intracellular transcription factors such as the nuclear hormone receptor (NR) 
family of ligand-activated transcription factors, and members of the basic-helix-loop-
helix family of transcription factors such as carbohydrate response element-binding 
protein (ChREBP) and sterol regulatory element binding protein (SREBP) are activated by 
ligands or metabolites within the cell. 
 
G protein-coupled receptors  
The largest family of plasma membrane bound receptors are G protein-coupled 
receptors (GPCRs), characterized by 7 transmembrane loops and intracellular G protein 
signaling (reviewed in[44,45]). The GPCR-superfamily is involved in the detection of a 
wide range of signals including nutrients, bile acids, SCFAs, (gut) hormones and 
neurotransmitters. With about one third of FDA approved therapeutics on the market 
today targeting this family, GPCRs are the largest group of drug targets for a wide variety 
of diseases[46–49]. Since these receptors can be activated by agonists present in the 
intestinal lumen, many GPCR targeted drugs can be taken orally. For example, TGR5, also 
known as G protein-coupled bile acid receptor 1 (GPBAR1), is activated by bile acids in 
enteroendocrine L-cells and increases the proglucagon expression. Systemic activation 
of TGR5 protects against diet-induced obesity via increased energy expenditure and 
regulates glucose homeostasis via induced GLP-1 production in animal models[50–52]. 
However, this was also associated with gall bladder and heart problems[53]. Intestine-
specific TGR5 ligands have therefore been developed to enhance GLP-1 release while 
avoiding systemic adverse effects[54,55]. This demonstrates the potential of intestinal 
GPCRs as putative drug targets for anti-diabetic therapy and indeed more studies are 
now conducted in this research field[48,56,57].  
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ChREBP and SREBP 
An adequate postprandial response to carbohydrate intake on de novo lipogenesis is 
regulated via the activation of ChREBP and SREBP1c by glucose and insulin, respectively. 
Insulin regulates SREBP1c, the hepatic activator of de novo lipogenesis and thereby 
mediates the induction of lipogenic gene expression in response to glucose 
intake[58,59]. In response to intracellular sugar levels, the glucose-activated 
transcription factor ChREBP activates target genes involved in glycolytic and lipogenic 
pathways and is also required to mediate a postprandial response (reviewed in[60]). 
Synergistic actions of these transcription factors have been discovered, which were at 
least partly mediated by the sterol sensor LXR (Figure 1)[59]. 
 
Figure 1. Regulation of hepatic lipogenesis 
requires the concerted actions of ChREBP, 
LXR, and SREBP-1c. This schematic depicts the 
synergistic action of insulin and 
fructose/glucose in promoting hepatic 
lipogenesis. Insulin increases SREBP-1c mRNA 
as well as the proteolytic processing of SREBP-
1c protein, whereas fructose/glucose activates 
ChREBP. SREBP-2, which regulates genes of 
cholesterol biosynthesis, controls the 
production of endogenous sterol ligands to 
activate LXR. LXR regulates the transcription of 
SREBP-1c, ChREBP and other lipogenic genes. 
ChREBP also directly regulates SREBP-1c 
expression and, at least under certain 
conditions, SREBP-1c can also regulate 
ChREBP. Together, SREBP-1c, LXR, and ChREBP 
are required for maximal induction of 
postprandial hepatic lipogenesis[59]. 
 
After activation by glucose or glucose metabolites such as glucose-6-phosphate, 
ChREBP migrates to the nucleus. Together with its dimerization partner Max-like protein 
X (Mlx), ChREBP binds to the promoter of target genes to control transcription[60]. In 
2012, the isoform ChREBPb was discovered as the most potent activator of ChREBP 
target genes[61]. ChREBPa is the more glucose-responsive isoform and is a positive 
regulator of ChREBPb, completing a positive feedforward pathway. ChREBPs are 
ubiquitously expressed and recently the importance of intestine-specific ChREBP in 
fructose absorption and metabolism was highlighted. Similar to the whole-body ChREBP 
knockout mice, intestinal-specific ChREBP deficient mice displayed fructose 
malabsorption and intolerance[62,63]. In contrast, hepatic ChREBP was not essential for 
fructose metabolism, at least partly because hepatic ChREBP does not control first-pass 
fructose absorption whereas intestinal ChREBP governs fructose transporter Glut5 levels 
in the small intestine.  
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The SREBP-family consist of 3 members; SREBP1a, SREBP1c and SREBP2, which are 
key regulators of lipid- and cholesterol metabolism and predominantly expressed in 
metabolically active tissues[64]. SREBP2 regulates cholesterol metabolism, and induces 
the synthesis of endogenous oxysteroid ligands to activate LXR, which subsequently 
leads to lipogenic gene activation via SREBP1c, a major target gene of LXR[65]. SREBP1c 
predominantly regulates hepatic triglyceride and fatty acid synthesis. In addition, 
SREBP1c is under the transcriptional control of insulin, resulting in enhanced lipogenic 
activity after glucose intake. SREBP precursors are inactive and located in the 
endoplasmic reticulum (ER). These precursors are transported towards the Golgi when 
intracellular sterol levels are low. Inside the Golgi, SREBPs are processed by proteases to 
reach their mature, active forms. Mature SREBPs can enter the nucleus where they exert 
their transcriptional regulation to restore sterol homeostasis (reviewed in[64,65]).  
 
Nuclear Receptors 
The nuclear receptor (NR) family consist of 48 members in humans (49 members in 
mice) and are ligand-activated transcription factors. NRs govern the transcriptional 
regulation of genes involved in a multitude of biological processes including 
inflammation, differentiation, reproduction and metabolism[66]. The best known NR 
ligands are the steroid hormones but also a wide variety of other small lipophilic 
molecules like bile acids, fatty acids, oxysterols and xenobiotics can serve as natural 
ligands for NRs (reviewed in[67]). For many NRs, the so-called orphan receptors, a 
physiological ligand has not been identified. After ligand binding, activated NRs bind 
directly to a hormone response element (HRE) sequence in the promoter region of 
target genes to regulate their transcription. NRs can also directly bind to other 
transcription factors thereby obstructing their actions. This indirect mechanism is called 
transrepression and is predominantly seen in the regulation of inflammation[68]. The 
work in this dissertation focuses on the role of intestinal NRs in controlling systemic 
metabolism and this will be discussed more extensively in the next sections.  
 
Pharmaceutical potential of nuclear receptors 
The NRs are one of the largest groups of drug targets, with about 16% of FDA 
approved therapeutics on the market today targeting this family, including drugs for the 
treatment of insulin resistance (glitazones, TZDs), hyperlipidemia (fibrates), 
inflammation (dexamethasone) and cancer (tamoxifen)[49]. Development of synthetic 
ligands with agonistic (full, partial, dual, inverse) or antagonistic effects have provided 
novel therapeutics and research tools to study NR function, which resulted in a major 
leap forward in NR research[66]. 
 
Drugs that exert their effects via NR activation also include glucose lowering 
therapies. For example, thiazolidinediones (TZDs) bind and activate the peroxisome 
proliferator-activated receptor gamma (PPARg) causing an insulin sensitizing effect[69]. 
Despite their efficacy in glycemic control, TZDs are associated with various serious 
adverse side effects, including weight gain, fluid retention, osteoporosis and 
cardiovascular toxicity, which has strongly limited their clinical use. Current research on 
PPARγ and other NRs therefore focuses on the development of partial agonists, or so- 
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called selective pharmacologic modulators, which either act only on a subset of genes or 
have tissue specific activity in order to circumvent systemic off-target effects (Figure 
2,[70,71]). Another approach to minimize adverse effects of drugs targeting NRs is via 
directly targeting of downstream targets. An example of a downstream target of PPARγ 
with anti-diabetic activity is fibroblast growth factor 1 (FGF1)[72].  
 
 
Figure 2. Nuclear receptor 
mechanisms of action. 
Schematic illustrating the 
principle of selective receptor 
modulation. NRs are regulated 
by small molecule ligands, 
which generally stabilize the 
receptor into a conformation 
suitable to bind coregulator 
proteins (coactivators or 
corepressors). Ligands can also 
modulate posttranslational 
modification of the receptor. 
Ultimately, these events have 
an impact on the expression of 
receptor-specific target genes 
by modulating coregulator 
recruitment at specific DNA-
response element sites in the 




Nuclear hormone receptors in the intestine  
Considering the emerging acknowledgement of gastrointestinal control in systemic 
energy homeostasis, intestine-specific NR activation has recently gained popularity as a 
strategy to regulate systemic energy balance. Many NRs are expressed in the 
gastrointestinal tract but their specific roles in this tissue remain largely unexplored[73–
75] So far, NRs in the intestine have been demonstrated to be involved in a wide variety 
of (patho-) physiologies. NRs in the gut regulate metabolism by controlling metabolic 
genes involved in intestinal inflammation, gut hormone secretion, nutrient absorption 





Regulation of the enterohepatic circulation 
As mentioned previously, the gut microbiota governs whole-body metabolism via 
various pathways, including influencing the bile acid pool size and composition. For 
instance, gut microbiota can induce GATA4 and, thereby, inhibit the intestinal bile acid 
transporter ABST blocking the recycling of bile acids[35]. The intestinal NR Farnesoid X 
receptor (FXR) is a bile acid sensor and influences energy metabolism in response to 
changes in the bile acid pool, while FXR in turn also controls the bile acid 
homeostasis[78,79] (Figure 3).  
 
Figure 3. Model of negative feedback regulation of hepatic bile-acid synthesis via FXR 
in a tissue-specific manner[80]. Bile acids are synthesized by hepatocytes, secreted into 
the bile and released from the gallbladder into the small intestine upon feeding to assist 
in lipid absorption. Approximately 95% of the bile acids are reabsorbed in the ileum and 
transported back to the liver. Intestinal FXR is activated by bile acids in the gut and 
induces the production and secretion of hormone fibroblast growth factor 19 (FGF19) 
(FGF15 in mice) which in turn suppresses bile acid synthesis via CYP7A1 in hepatocytes 
thereby completing the negative feedback cycle[81].  
 
Besides FXR, the NRs Vitamin D receptor (VDR) and Pregnane X receptor (PXR) are 
also activated by bile acids in the intestine. Similar to FXR, VDR induces FGF15 to reduce 
hepatic bile acid synthesis in mice and thereby controls bile acid homeostasis[82]. 
Intestinal VDR has also been demonstrated to protect against colon cancer[83]. PXR is a 
xenobiotic sensor that is activated by many ligands including bile acids, steroid 
hormones and xenobiotic compounds. Intestinal PXR activation leads to increased 
cholesterol uptake from the intestinal lumen via Niemann-Pick C1-Like 1 (NPC1L1), CD63 
and other lipogenic target genes, thereby linking a high xenobiotic exposure to the 
increased prevalence of chronic metabolic diseases[84,85],[86].  
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Systemic FXR activation is associated with reduced cholesterol and triglyceride levels 
in liver and plasma in mice[87] and improved glycemic control in wild-type mice and 
db/db mice[88]. Interestingly, Fang et al showed that intestinally-restricted FXR 
activation by a non-absorbable FXR ligand named Fexaramine[89] protected against 
weight gain and improved the glucose tolerance and insulin sensitivity in mice during a 
HFD challenge, highlighting the role of intestine-specific FXR in maintaining metabolic 
homeostasis. However, increased energy expenditure by enhanced browning of adipose 
tissue in mice treated with Fexaramine was at least partly mediated by TGR5 signaling, 
since TGR5 deficient mice treated with Fexaramine were blunted in these metabolic 
improvements[74].  
 
Intestine-specific inhibition of FXR signaling in mice has also been investigated using 
glycine-β-muricholic acid (Gly-MCA) treatment demonstrating that intestinal FXR 
deficiency protected against diet-induced obesity and obesity-related metabolic 
derangements[75]. These seemingly contradictory results of intestinal FXR actions can 
be explained by the differential activation of the TGR5 pathway. Whereas, TGR5 was 
activated by fexaramine, this was not case upon Gly-MCA treatment[75]. These studies 
indicate the complexity of the molecular pathways by which NRs govern metabolism. 
 
Glycemic regulation 
Several NR members including hepatocyte nuclear factor 4 gamma (HNF-4γ), FXR and 
PPARδ have been suggested to regulate intestinal expression of the proglucagon gene 
which encodes incretins such as GLP-1 and GIP[90],[91],[92]. As mentioned above, 
incretin-related drugs have insulinotropic properties and are therefore promising 
treatments to improve the metabolic status. Consequently, targeting NRs that regulate 
incretin production may also have potential as a new therapeutic strategy[93]. HNF-4γ 
deficient mice displayed increased proglucagon gene expression and GLP-1 
secretion[90]. FXR deficiency improved glycemic control in mice fed a HFD, which is 
mediated by GLP-1 levels. In addition, FXR activation directly decreased proglucagon 
mRNA levels in human and mice[91]. Together, these data suggest that intestinal 
antagonist treatment of HNF-4γ and FXR can be beneficial to ameliorate glucose control 
via incretin actions. On the other hand, PPARd activation by the selective agonist 
GW501516 increased proglucagon gene expression and GLP-1 secretion in mice resulting 
in improved glucose tolerance[92]. This suggests that intestinal activation of 






Regulation of cholesterol metabolism 
High density lipoprotein cholesterol (HDL-c) exerts a transport function in the reverse 
cholesterol transport (RCT) pathway, which reduces the lipid deposition in the peripheral 
tissues, a process associated with the protection against cardiovascular diseases and 
atherosclerosis (Figure 4). Approximately 30% of pre-β HDL particles are produced in the 
intestine and 70% in the liver[94,95]. ATP-binding cassette A1 (ABCA1) transports 
cholesterol and phospholipids into lipid-free apolipoproteins which is a rate-limiting step 





Figure 4. Sterol fluxes across the enterocyte. At the apical membrane, Free cholesterol 
(FC) is taken up by NPC1L1 protein and can be directed to ACAT2-mediated esterification 
and subsequent secretion in chylomicrons via MTP. FC can be secreted as an HDL 
component by the basolateral transporter ABCA1 or can be effluxed back into the 
intestinal lumen by the apical heterodimer ABCG5/G8. Enterocytes are also actively 
excreting plasma-derived cholesterol in a process named TICE, however the underlying 
mechanisms remain to be uncovered (adapted from:[98]). 
 
Dietary and biliary cholesterol in the intestinal lumen is absorbed via the cholesterol 
transporter Niemann Pick C 1 like 1 (NPC1L1), which expression is upregulated by the 
NRs PPARa[99] and HNF4a[100] and downregulated by LXR[101] and PPARd[102]. The 
heterodimer ATP-binding cassette (ABC) transporters G5 (ABCG5) and G8 (ABCG8) 
counteract the function of NPC1L1 by transporting cholesterol back into the intestinal 
lumen. LXR activation increases Abcg5 and Abcg8 gene expression resulting in enhanced 
cholesterol secretion[103]. Overall, LXR controls many genes in lipid metabolism 
resulting in increased cholesterol efflux, HDL plasma levels and hepatic lipogenesis upon 
systemic LXR activation[104]. Synthetic agonists targeting LXR are therefore putative 
drugs to treat atherosclerosis. However, until now no LXR agonists have reached the 
clinic due to serious side effects[105]. The main side effect is caused by LXR activation in 
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hepatocytes which induces lipogenic activity and drives the development of non-
alcoholic fatty liver disease (NAFLD). Intestine-specific LXR activation could therefore be 
a strategy to circumvent the hepatic adverse effects while still inducing the therapeutic 
benefits. To study this, a villin-specific constitutively active LXRa transgenic mouse 
model has been developed[73]. Indeed, intestinal LXRa activation stimulated 
macrophage-mediated RCT, without inducing lipid accumulation in hepatocytes. 
Intestine-specific LXRa activation also decreased cholesterol absorption and induced 
HDL plasma levels via increased expression of known intestinal LXR targets Abcg5/Abcg8 
and Abca1. An intestine selective activation of LXR was also observed for the selective 
agonist GW3965 possibly via alternative recruitment of co-activators[106]. GW3965 
treatment of mice by oral gavage induced HDL-c levels in an intestine-specific, Abca1 
dependent manner and this was not associated with hepatic de novo lipogenesis[96]. 
Intestine-specific LXR activation might thus be a great strategy to treat atherosclerosis 
while avoiding the development of a fatty liver.  
In conclusion, understanding the molecular mechanisms by which intestine-specific 
NRs regulate metabolism is important to develop more effective and safer drugs while 
limiting off-target effects.  
 
 
Aim and outline of this thesis 
 
The general aim of this thesis was to explore the potential of intestinal NR activation 
in the regulation of whole-body energy homeostasis. While systemic activation of NRs 
has been successfully applied in the pharmaceutical industry, it often causes major 
adverse effects due to the pleiotropic target genes of NRs. Only recently, the importance 
of the gut as an endocrine organ with a major role in whole body energy homeostasis 
has been underscored. Selective activation of NRs in the gut might therefore prove to be 
an effective way of inducing beneficial effects on metabolism while avoiding, or at least 
minimizing, systemic toxicity. 
 
High fructose consumption is implicated as an important factor in the development 
of metabolic syndrome, however, no consensus has been reached on the precise role 
and impact of dietary fructose. Moreover, recently it has been demonstrated that the 
gut has a more dominant role than the liver in determining the fate of dietary 
fructose[63,107]. In chapter 2 we therefore aimed to gain more insight in the specific 
effects of fructose on the intestine by investigating the changes in the intestinal and 
hepatic transcriptome after a 2-weeks high-carbohydrate challenge of dietary fructose 
as compared to glucose or cornstarch in mice. 
 
The GLUT-family of facilitative hexose transporters is essential to effectively absorb 
simple sugars from the intestinal lumen and transport them throughout the body and to 
tissues where they can be utilized. To match sugar uptake with energy demand, the 
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expression levels of GLUT-members are tightly controlled by various regulatory 
mechanisms. The intestinal expression and regulation of members the GLUT-family of 
hexose transporters, however, is not well-studied and their contribution to the 
development of metabolic disorders remains largely unknown. In chapter 3 we set out 
to identify novel transcriptional regulators of the 14 human GLUT-members. For this, we 
used a high-throughput promoter reporter screen testing for regulation by all 49 
members of the nuclear receptor (NR) family, a superfamily of ligand-modulated 
transcription factors (TFs) as well as by NR co-regulator peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC1a) and glucose-activated 
transcription factors ChREBPa and -b. In addition we profiled the expression of members 
of the GLUT-family in human Caco2 cells and validated several of the newly identified 
regulations of intestinal GLUTs in this in vitro model of the small intestine. Fructose 
absorption in the small intestine is primarily mediated by GLUT5, which makes this 
transporter indispensable to absorb our modern high-fructose diet. The physiological 
function of GLUT7, a protein with 53% amino acid similarity to GLUT5, is still largely 
unknown. Moreover, the physiological substrate of GLUT7 is the subject of an ongoing 
discussion and no consensus has been reached about its ability to transport fructose 
and/or glucose[108–111]. The transcriptional regulation of these two fructose 
transporters, GLUT5 and GLUT7, was further investigated in chapters 4 and 5, 
respectively. Understanding how these transporters are regulated will not only enhance 
basal knowledge of fructose absorption and metabolism but might also help to assess 
the role of high fructose consumption in the development of metabolic syndrome. 
 
In the final experimental chapter, we focused on the role of peroxisome proliferator-
activated receptor d (PPARd) in the intestine. PPARd is well known for its role in fatty 
acid oxidation in adipose tissue and skeletal muscle and improves dyslipidemia in mice 
and humans. Although PPARd is abundantly expressed along the entire intestinal tract, 
its potential role in energy homeostasis in this organ has not been well explored. In 
chapter 6 we therefore investigated the role of intestinal PPARd activation on whole 
body metabolism using mice with an intestinal epithelial cell-specific deletion of PPARd 
(PPAR-deltaIEC-KO). PPARd plays an important role in energy homeostasis; systemic PPARd 
activation with the ligand GW501516 improves plasma lipid profile and protects against 
diet-induced obesity in mice, however, the role of intestine-specific PPARd remained to 
be elucidated[112]. Here we investigated the metabolic effects of a high-fat diet and 
treatment with the selective PPARd agonist GW501516 in mice with a specific deletion 
of PPARd in the intestine (PPAR-deltaIEC-KO mice).  
Finally, chapter 7 discusses the main findings of this thesis and gives 
recommendations for future research.   
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